引用本文:王彦,赵宝霞,于志红,刘敏,车耀润,王朝晖,吕申.子宫颈癌hMLH1表达及细胞增殖活性研究[J].大连医科大学学报,2004,26(1):.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 次   下载  
分享到: 微信 更多
子宫颈癌hMLH1表达及细胞增殖活性研究
王彦1, 赵宝霞1,2, 于志红1, 刘敏3, 车耀润1, 王朝晖1,2, 吕申1,2
1.大连医科大学,第二临床学院分子生物学实验室,辽宁,大连,116027;2.大连医科大学,病理学教研室,辽宁,大连,116027;3.大连市妇产医院,辽宁,大连,116027
摘要:
了解错配修复基因hMLH1蛋白与增殖细胞核抗原(PCNA)在子宫颈癌中的表达,分析它们与子宫颈癌临床病理生物学行为的关系及在子宫颈癌发病中的意义。[方法] 免疫组织化学SP法检测62例宫颈癌和30例非癌子宫颈上皮细胞hMLH1蛋白与PCNA表达的情况,并分析二者的关系及它们的表达与病理参数的关系。 [结果] hMLH1蛋白在子宫颈癌组阳性表达率为56.5%,低于非癌上皮组的63.3%;PCNA在子宫颈癌组阳性表达率为79.0%,明显高于在非癌上皮组的20.0%(P<0.05)。子宫颈癌组hMLH1蛋白表达阳性例PCNA的阳性表达率82.9%高于hMLH1蛋白表达阴性例的74.1%;非癌上皮组hMLH1表达阳性例PCNA阳性表达率26.3%也高于hMLH1蛋白表达阴性例的蛋白蛋白9.1% ,即在hMLH1蛋白高表达的组织中PCNA表达增高。hMLH1蛋白阳性表达率在临床Ⅰ期、Ⅱ期、Ⅲ期子宫颈癌分别为61.4%、46.7%、33.3%,有逐渐降低趋势;在高、中分化鳞癌与低分化鳞癌分别为60%与52.3%;淋巴结转移组为50%(4/8),无淋巴结转移组为64.4%(29/45)。PCNA阳性表达率在临床Ⅰ期、Ⅱ期、Ⅲ期子宫颈癌分别为81.8%、73.3%、66.7%;在高、中分化鳞癌与低分化鳞癌分别为71.8%与91.3%;淋巴结转移组为87.5%(7/8), 无淋巴结转移组为84.4%(38/45)。[结论] 子宫颈癌细胞PCNA表达与hMLH1蛋白表达相关,二者的表达可能参与子宫颈癌的发生过程。
关键词:  子宫颈癌  hMLH1  PCNA
DOI:10.11724/jdmu.2004.01.01
分类号:R737.33
基金项目:
Cell proliferation associating with hMLH1 protein expression in cervical carcinoma
WANG Yan,ZHAO Bao-xia,LIU Min,CHE Yao-run,WANG Zhao-hui,L Shen
1.Laboratory of Molecular Biology, the Second Hospital of Dalian Medical University, Dalian 116027, China;2.Department of Pathology, Dalian Medical University, Dalian 116027, China
Abstract:
To illustrate the expression of hMLH1 protein and prolifer ating cell nuclear antigen (PCNA) and to analyze effect of the expression on pathological factors in carcinogenesis of the cervical carcinoma. [Methods] Formalin-fix and paraffin-embedded tissues from 62 cases of cervical carcinoma and 30 cases of non-carcinoma cervical tissues were used to detect protein expression of hMLH1 and PCNA by immunohistochemistry method. [Result] The expression rates of hMLH1 in cervical carcinoma and non-carcinoma cervical tissues were 56.5% and 63.3% respectively. The expression rate of PCNA in cervical carcinoma being 79.0% was higher than that in non-carcinoma cervical tissues being 20.0%(P<0.05).The expression rate of PCNA in the tissues with the hMLH1 expression was higher than that without the expression in either cervical carcinoma or non-carc inoma cervical tissues. The expression rates of hMLH1 were gradual decrease with clinical stage and pathological grades ; the expression sates of hMLH1 in cervical carcinoma with lymph node metastasis and without were 50%(4/8)and 64.4%(29/45)respectively. The expression rates of PCNA of cervical carcinoma with the clinical Ⅰ,Ⅱ and Ⅲ stages were 81.8%, 73.3% and 66.7% respectively. The expression rates of PCNA in cervical carcinoma with well-middle and poor differ entiation were 71.8% and 91.3% respectively, and the expression rates of PCNA in cervical carcinoma with lymph node metastasis and without were 87.5%(7/8) and 84.4%(38/45). [Conclusion] The expression of hMLH1 are related to the expression of PCNA in the cervical carcinoma and their expressions may participate in the carcinogenesis of cervical carcinoma
Key words:  cervical  hMLH1  PCNA